Syneos Health Appoints Michael Bonello as Chief Financial Officer
May 02 2023 - 5:19AM
Syneos Health® (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, today announced the
appointment of Michael Bonello as Chief Financial Officer,
effective July 1, 2023. Stanford (Ben) Rudnick will continue to
serve as Interim Chief Financial Officer until that time.
Mr. Bonello has more than 30 years of financial leadership
experience, including 15 years in the clinical research industry.
He most recently served as Chief Financial Officer of Clario, Inc.,
a clinical trial data collection company, since 2021. From 2008 to
2021, Mr. Bonello held roles of increasing responsibility at
Nasdaq-listed PRA Health Sciences, Inc., including Executive Vice
President and Chief Financial Officer from 2018 through the
company’s sale to ICON plc, and previously as Senior Vice
President, Accounting and Corporate Controller from 2008 to 2018.
Earlier in his career, he held financial leadership roles at Cree,
Inc. and Genworth Financial, and was a senior manager in the audit
practice at PricewaterhouseCoopers LLP. Mr. Bonello is a certified
public accountant.
“With decades of relevant finance expertise – and significant
clinical research industry experience – Mike is ideally suited to
serve as our next Chief Financial Officer. As we further transform
Syneos Health for the technology and data-powered future of
clinical development and commercialization, I look forward to
working with Mike and our entire team to execute on our growth,
innovation and efficiency goals,” said Michelle Keefe, CEO of
Syneos Health.
“Syneos Health is well regarded for its integrated strategy and
leading solutions supporting customers’ development and
commercialization objectives,” Mr. Bonello said. “I am excited to
partner with Michelle, the rest of the management team and the
talented employees across the organization to drive growth and
value for all stakeholders.”
About Michael Bonello
Mr. Bonello previously served as the Chief Financial Officer of
Clario, Inc., a clinical trial data collection company, from
November 2021 to present. Prior to that role, from May 2018 to
August 2021, he served as Executive Vice President and Chief
Financial Officer of PRA Health Sciences, Inc. (“PRA”), a former
contract research organization that was acquired by ICON plc in
2021. Mr. Bonello previously served as Senior Vice President,
Accounting and Corporate Controller for PRA, after having joined
the company in March 2008. Prior to PRA, Mr. Bonello held positions
with Cree, Inc., where he was Director of Finance/Corporate
Controller, and Genworth Financial (formerly GE Mortgage Insurance
Corporation) where he served as Vice President, Domestic Controller
and Global Reporting Leader. Mr. Bonello also served for seven
years in the audit practice at PricewaterhouseCoopers LLP. He
received a B.B.A. with a concentration in accounting from St.
Bonaventure University.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated
biopharmaceutical solutions organization built to accelerate
customer success. We translate unique clinical, medical affairs and
commercial insights into outcomes to address modern market
realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and
apply advanced business practices to speed our customers’ delivery
of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance from lab
to life®, visit syneoshealth.com or subscribe to our podcast.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995, including statement’s
regarding our future financial results, transformation efforts and
strategy. Actual results might differ materially from those
explicit or implicit in the forward-looking statements. Important
factors that could cause actual results to differ materially
include, but are not limited to: the Company’s potential failure to
generate a large number of new business awards and the risk of
delay, termination, reduction in scope, or failure to go to
contract of our business awards; the Company’s potential failure to
convert backlog to revenue; fluctuations in the Company’s operating
results and effective income tax rate; and other risk factors set
forth in the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 as updated by the Company’s other SEC
filings, copies of which are available free of charge on the
Company's website at investor.syneoshealth.com. The Company assumes
no obligation and does not intend to update these forward-looking
statements, except as required by law.
Investor Relations ContactRonnie SpeightSenior
Vice President, Investor Relations+1 919 745
2745Investor.Relations@syneoshealth.com
Media ContactGary GatyasExecutive Director,
External Communications+1 908 763
3428gary.gatyas@syneoshealth.com
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024